<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Adefovir Dipivoxil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00718</strong>&#160; (APRD00781)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Adefovir dipivoxil, previously called bis-<span class="caps">POM</span> <span class="caps">PMEA</span>, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against <span class="caps">HIV</span>-1. [Wikipedia] Adefovir dipivoxil is the diester prodrug of adefovir.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00718/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00718/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00718.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00718.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00718.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00718.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00718.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00718">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ad&#233;fovir</td><td>French</td><td>INN</td></tr><tr><td>Adefovir</td><td>German/Spanish</td><td>INN</td></tr><tr><td>Adefovir Pivoxil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>JAN</td></tr><tr><td>Adefovirum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>A Di Xian</td><td>The United Laboratories Ltd</td></tr><tr><td>A Gan Ding</td><td>Fujian Guangsheng Tang</td></tr><tr><td>Adesera</td><td>Cipla</td></tr><tr><td>Adfovir</td><td>Sun Pharmaceutical Industries Ltd.</td></tr><tr><td>Ailuwei</td><td>Changzheng-Xinkai</td></tr><tr><td>Antiva</td><td>Square</td></tr><tr><td>Biovir</td><td>Ivax</td></tr><tr><td>Dai Ding</td><td>Tianjin Institute of Pharmaceutical Research</td></tr><tr><td>Dinghe</td><td>Lukang</td></tr><tr><td>Hepsera</td><td>Gilead Sciences, Inc.</td></tr><tr><td>Infovir</td><td>Incepta</td></tr><tr><td>Jiule</td><td>Fovir Pharm</td></tr><tr><td>Lifuzhi</td><td>Jiangsu TianShiLi BeiTe Pharmaceutical Co., Ltd.</td></tr><tr><td>Ming Zheng</td><td>Chia Tai Tianqing</td></tr><tr><td>Nafasera</td><td>Vidipha</td></tr><tr><td>Preveon</td><td>Gilead Sciences, Inc.</td></tr><tr><td>Pymefovir</td><td>PMP</td></tr><tr><td>Xinfunuo</td><td>SL Pharm</td></tr><tr><td>Yilaifen</td><td>Qilu</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antiviral-agents">Antiviral Agents</a></li>
<li><a href="/mesh/reverse-transcriptase-inhibitors">Reverse Transcriptase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>142340-99-6</td></tr><tr><th>Weight</th><td>Average: 501.4705<br>Monoisotopic: 501.198849537</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>32</sub>N<sub>5</sub>O<sub>8</sub>P</td></tr><tr><th>InChI Key</th><td>WOZSCQDILHKSGG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">[({[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}({[(2,2-dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Imidazopyrimidines</td></tr><tr><th>Subclass</th><td>Purines and Purine Derivatives</td></tr><tr><th>Direct parent</th><td>Purines and Purine Derivatives</td></tr><tr><th>Alternative parents</th><td>Aminopyrimidines and Derivatives; Primary Aromatic Amines; Phosphonic Acid Esters; Dicarboxylic Acids and Derivatives; N-substituted Imidazoles; Carboxylic Acid Esters; Enolates; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>aminopyrimidine; primary aromatic amine; phosphonic acid ester; dicarboxylic acid derivative; pyrimidine; n-substituted imidazole; imidazole; azole; phosphonic acid derivative; carboxylic acid ester; polyamine; carboxylic acid derivative; ether; enolate; primary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the purines and purine derivatives. These are aromatic heterocyclic compounds containing a purine moiety, which is formed a pyrimidine-ring ring fused to an imidazole ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</td></tr><tr><th>Pharmacodynamics</th><td>Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 &#956;M in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity.</td></tr><tr><th>Mechanism of action</th><td>Adefovir dipivoxil is a prodrug of adefovir. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 &#956;M. Adefovir diphosphate is a weak inhibitor of human DNA polymerases &#945; and &#947; with Ki values of 1.18 &#956;M and 0.97&#956;M, respectively.</td></tr><tr><th>Absorption</th><td>The approximate oral bioavailability of adefovir from HEPSERA is 59%. When a single oral 10 mg dose is given to chronic hepatitis B patients, the peak plasma concentration (Cmax) of adefovir was 18.4 &#177; 6.26 ng/mL. This occurred between 0.58 - 4 hours post dose (Tmax). The adefovir area under the plasma concentration-time curve (AUC0&#8211;&#8734;) was 220 &#177; 70.0 ng&#8729;h/mL. Food does not affect the exposure of adeforvir. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>392 &#177; 75 mL/kg [Vd at steady state, intravenous administration of 1.0 mg/kg/day]</li>
	<li>352 &#177; 9 mL/kg [Vd at steady state, intravenous administration of 3.0 mg/kg/day]</li>
</ul></td></tr><tr><th>Protein binding</th><td>&#8804;4% over the adefovir concentration range of 0.1 to 25 &#956;g/mL</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Following oral administration, adefovir dipivoxil is rapidly converted to adefovir. 45% of the dose is recovered as adefovir in the urine over 24 hours at steady state following 10 mg oral doses. Adefovir is not a substrate of the cytochrome P450 enzymes.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Adefovir Dipivoxil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01173">Adefovir</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1316">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01173">Adefovir</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0001262" target="_blank">Adenylate kinase isoenzyme 1</a></li>
<li><a href="/biodb/bio_entities/BE0004477" target="_blank">Adenylate kinase 2, mitochondrial</a></li></ul></td><td><a href="/metabolites/DBMET01174">Adefovir monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1317">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01174">Adefovir monophosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003106" target="_blank">Nucleoside diphosphate kinase A</a></li>
<li><a href="/biodb/bio_entities/BE0003281" target="_blank">Nucleoside diphosphate kinase B</a></li></ul></td><td><a href="/metabolites/DBMET01175">Adefovir Diphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1318">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Adefovir is renally excreted by a combination of glomerular filtration and active tubular secretion.</td></tr><tr><th>Half life</th><td>Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 &#177; 1.65 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>469 &#177; 99.0 mL/min [Patients with Unimpaired renal Function receiving a 10 mg single dose]</li>
	<li>356 &#177; 85.6 mL/min [Patients with mild renal impairement receiving a 10 mg single dose]</li>
	<li>237 &#177; 118 mL/min [Patients with moderate renal impairement receiving a 10 mg single dose]</li>
	<li>91.7 &#177; 51.3 mL/min [Patients with severe renal impairement receiving a 10 mg single dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Renal tubular nephropathy characterized by histological alterations and/or increases in BUN and serum creatinine was the primary dose-limiting toxicity associated with administration of adefovir dipivoxil in animals. Nephrotoxicity was observed in animals at systemic exposures approximately 3&#8211;10 times higher than those in humans at the recommended therapeutic dose of 10 mg/day.</td></tr><tr><th>Affected organisms</th><td><ul><li>Hepatitis B virus</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Adefovir Dipivoxil Action Pathway</td><td>Drug action</td></tr><tr><td>Adefovir Dipivoxil Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00629?highlight%5Bcompounds%5D%5B%5D=DB00718&amp;highlight%5Bproteins%5D%5B%5D=DB00718">SMP00629</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9023</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8905</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6281</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7113</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5465</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.896</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8273</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9234</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8305</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5584</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7508</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.725</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7985</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7005</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7139</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8392</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5535
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.828
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9762
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6261 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6903
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7412
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Gilead sciences inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.excella-pharma-source.de">Excella GmbH</a></li>
<li><a href="http://www.gilead.com">Gilead Sciences Inc.</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01610">Valganciclovir</a></td><td>The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Adefovir Dipivoxil, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>